Connect with us

Health

EMA recommends approval of six medicines, expands indications for nine

SHARE:

Published

4 months ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

EMA’s human medicines committee (CHMP) published the outcomes of their meeting on Friday (30 January). EMA recommended six medicines for approval at its meeting and extended the therapeutic indications of nine medicines.

Here are some highlights:

Menopause: The committee recommended marketing authorisation for Fylrevy (estetrol),  a hormone replacement therapy for oestrogen deficiency symptoms in postmenopausal women who have had a hysterectomy, made by Hungarian company Gedeon Richter Plc.

GR’s Head of Women’s Healthcare (WHC), Dr Péter Turek, Business Unit, said that it was an important milestone, saying it may be the first innovative hormonal therapy for menopause in the European market in decades. 

“Bringing an original product to the market – our second, based on the unique, proprietary Estetrol platform – would be a major achievement for Richter. It reflects our unwavering commitment to improving the quality of life of women globally, validates our strategy to invest in original research, and further strengthens our leading position in Europe.”

Cancer: Use of Zynyz in the treatment...

Advertisement

Share this article:

Share this:
Related Topics:
Guest Contributor - Opinion

Opinions expressed are purely those of the author and not endorsed by EU Reporter. The article was unsolicited by EU Reporter, and the author guarantees the truthfulness of the contents of the article. No payment was made by EU Reporter to the author

EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Advertisement

Trending